"目录号: HY-13733
Cell Cycle/DNA Damage-
Procarbazine盐酸盐为抗肿瘤烷化剂，可作用于霍奇金氏淋巴瘤和一些脑癌。
DNA Alkylator/Crosslinker
相关产品
Mitomycin C-Oxaliplatin-Temozolomide-Streptozocin-Carboplatin-Cyclophosphamide-Calicheamicin-Melphalan-Busulfan-Palifosfamide-Carmustine-RITA-SJG-136-Fotemustine-Lomustine-
生物活性
Description
Procarbazine Hcl, an antineoplastic chemotherapy drug, is an alkylating agent for the treatment of Hodgkin's lymphoma and certain brain cancers; also inhibits MAO thus increasing the effects of sympathomimetics, TCAs, and tyramine.Target: DNA alkylating agent; MAOThe mechanism of action is not fully understood. Metabolism yields azo-procarbazine and hydrogen peroxide which results in the breaking of DNA strands.Exposure to procarbazine hydrochloride by intraperitoneal injection caused tumors in rats and mice at several different tissue sites. In both rats and mice, it caused cancer of the brain (olfactory neuroblastoma) and hematopoietic system (lymphoma in rats and lymphoma or leukemia in mice). In rats, it also caused mammary-gland cancer (adenocarcinoma) in both sexes. In mice, it also caused benign lung tumors (adenoma) in both sexes and uterine cancer (adenocarcinoma) in females [1] [2].Procarbazine hydrochloride is an oral alkylating agent primarily used as a component of chemotherapy regimens for Hodgkin's lymphoma, as well as in regimens for primary central nervous system lymphoma and high-grade gliomas. After discontinuation of all drug therapy, exclusion of other potential etiologies, and resolution of hepatic injury, the patient was rechallenged with procarbazine and again experienced fever with aminotransferase level elevation [3].
Clinical Trial
NCT01737346
Incheon St.Mary's Hospital-National Cancer Center, Korea
Recurrent Glioblastoma Multiforme
October 2012
Phase 2
NCT00003564
M.D. Anderson Cancer Center-National Cancer Institute (NCI)
Brain and Central Nervous System Tumors
Phase 3
NCT00503594
Assistance Publique - Hôpitaux de Paris-French Innovative Leukemia Organisation
Lymphoma
July 2007
Phase 2
NCT00004004
New Approaches to Brain Tumor Therapy Consortium-National Cancer Institute (NCI)
Brain and Central Nervous System Tumors
July 1999
Phase 1-Phase 2
NCT00079092
Wake Forest University Health Sciences-National Cancer Institute (NCI)
Brain and Central Nervous System Tumors
January 2004
Phase 2
NCT00596154
Memorial Sloan Kettering Cancer Center
CNS Lymphoma-CNS Brain Cancer-Non-Hodgkin's Lymphoma
December 2004
Phase 2
NCT00003293
Pfizer
Brain and Central Nervous System Tumors
February 1998
Phase 3
NCT01399372
Radiation Therapy Oncology Group-National Cancer Institute (NCI)-NRG Oncology
Chemotherapeutic Agent Toxicity-Cognitive/Functional Effects-Lymphoma-Neurotoxicity-Radiation Toxicity
September 2011
Phase 2
NCT00074191
OHSU Knight Cancer Institute-National Cancer Institute (NCI)
Lymphoma
January 2000
Phase 2
NCT00002463
M.D. Anderson Cancer Center-National Cancer Institute (NCI)
Brain and Central Nervous System Tumors
February 1989
Phase 2
NCT00079105
Newcastle-upon-Tyne Hospitals NHS Trust
Lymphoma
January 2004
Phase 2
NCT00052455
Institute of Cancer Research, United Kingdom-National Cancer Institute (NCI)
Brain and Central Nervous System Tumors
October 2002
Phase 3
NCT00003929
Case Comprehensive Cancer Center-National Cancer Institute (NCI)
Lymphoma
June 1998
Phase 2
NCT00004010
Children's Oncology Group-National Cancer Institute (NCI)
Lymphoma
October 1999
Phase 2
NCT00151281
Weill Medical College of Cornell University
Non-Hodgkin's Lymphoma
November 2004
Phase 2
NCT00002806
Alliance for Clinical Trials in Oncology-National Cancer Institute (NCI)
Brain and Central Nervous System Tumors
July 1996
Phase 2
NCT00002840
European Organisation for Research and Treatment of Cancer - EORTC-Medical Research Council
Brain and Central Nervous System Tumors
August 1996
Phase 3
NCT00003114
Case Comprehensive Cancer Center-National Cancer Institute (NCI)
Lymphoma
July 1997
Phase 2
NCT00005796
Indiana University-Indiana University Melvin and Bren Simon Cancer Center
Bone Marrow Suppression-Brain and Central Nervous System Tumors-Drug/Agent Toxicity by Tissue/Organ
February 2000
Phase 1
NCT00335140
Eastern Cooperative Oncology Group
Lymphoma
December 2006
Phase 2
NCT00989352
University Hospital Freiburg-Universitätsklinikum Köln-Ludwig-Maximilians - University of Munich-University Hospital Heidelberg-University Hospital Ulm
Primary Non Hodgkin Lymphoma of the Central Nervous System
September 2009
Phase 2
NCT02333513
Hebei Yanda Hospital-Beijing Tiantan Hospital
Recurrent High-grade Glioma
February 2015
NCT01775475
AIDS Malignancy Consortium-National Cancer Institute (NCI)-The EMMES Corporation
AIDS-related Diffuse Large Cell Lymphoma-AIDS-related Diffuse Mixed Cell Lymphoma-AIDS-related Diffuse Small Cleaved Cell Lymphoma-AIDS-related Immunoblastic Large Cell Lymphoma-AIDS-related Lymphoblastic Lymphoma-AIDS-related Peripheral/Systemic Lymphoma-AIDS-related Small Noncleaved Cell Lymphoma-Stage III AIDS-related Lymphoma-Stage IV AIDS-related Lymphoma
September 2016
Phase 2
NCT00594815
Memorial Sloan Kettering Cancer Center-Northwestern Memorial Hospital-Columbia University-Kentuckiana Cancer Institute-University of Virginia-University of Vermont
Lymphoma
August 28, 2002
NCT00049439
Case Comprehensive Cancer Center-National Cancer Institute (NCI)
Lymphoma
March 1998
Phase 2
NCT00417014
Children's Cancer and Leukaemia Group-National Cancer Institute (NCI)
Lymphoma
NCT00002569
Radiation Therapy Oncology Group-National Cancer Institute (NCI)-North Central Cancer Treatment Group-Southwest Oncology Group-Eastern Cooperative Oncology Group-NCIC Clinical Trials Group
Brain and Central Nervous System Tumors
July 1994
Phase 3
NCT00003375
Radiation Therapy Oncology Group-National Cancer Institute (NCI)-Southwest Oncology Group-North Central Cancer Treatment Group-Eastern Cooperative Oncology Group-NRG Oncology
Brain and Central Nervous System Tumors
October 1998
Phase 2-Phase 3
NCT00002944
Children's Oncology Group-National Cancer Institute (NCI)
Brain Tumors-Central Nervous System Tumors
April 1997
Phase 3
NCT01468740
Harlachinger Krebshilfe e.V.-Deutsche AIDS Gesellschaft e.V.
HIV-associated Hodgkin Lymphoma
March 2004
Phase 2
NCT00433459
Christine Mauz-Körholz-Deutsche Krebshilfe e.V., Bonn (Germany)-Euronet Worldwide-Martin-Luther-Universität Halle-Wittenberg
Lymphoma
January 2007
Phase 3
NCT01251107
Fondazione Michelangelo
Hodgkin Lymphoma
March 2000
Phase 3
NCT00734773
Northwestern University-Pharmacyclics LLC.
Brain and Central Nervous System Tumors-Lymphoma-Neurotoxicity
November 2008
Early Phase 1
NCT02298283
The Lymphoma Academic Research Organisation
Hodgkin Lymphoma
April 2015
Phase 2
NCT00577993
M.D. Anderson Cancer Center-Genentech, Inc.
Lymphoma
March 1998
Phase 3
NCT01569204
University of Cologne
Hodgkin Lymphoma
October 2012
Phase 2
NCT00666484
University College, London
Lymphoma-Neurotoxicity
March 2008
Phase 2
NCT02661503
University of Cologne
Classical Hodgkin Lymphoma
July 2016
Phase 3
NCT00678327
Cancer Research UK-National Cancer Institute (NCI)
Lymphoma
August 2008
Phase 3
NCT01356680
University of Cologne
Hodgkin Lymphoma
December 2011
Phase 3
NCT00003113
Case Comprehensive Cancer Center-National Cancer Institute (NCI)
Lymphoma
July 1997
Phase 2
NCT00887146
Alliance for Clinical Trials in Oncology-National Cancer Institute (NCI)-European Organisation for Research and Treatment Center (EORTC)-NCIC Clinical Trials Group
Brain and Central Nervous System Tumors
September 2009
Phase 3
NCT00187057
St. Jude Children's Research Hospital-Children's Hospital of Philadelphia-National Cancer Institute (NCI)
Ataxia-Telangiectasia
September 2002
NCT00003788
Colorado Health Foundation-National Cancer Institute (NCI)
Brain and Central Nervous System Tumors
April 1998
Phase 3
NCT00003101
Memorial Sloan Kettering Cancer Center-National Cancer Institute (NCI)
Brain and Central Nervous System Tumors
August 1997
Phase 2